Company
Sift Biosciences
Borrowing Nature’s Playbook To Fight Cancer and Autoimmunity
- Status
- Operatingas of 2026-09-17
- Business model
- B2B
- Customers
- Top-10 Global Pharma
Claim, correct or request removal
Record updated 17 September 2026
About
Sift is building a proprietary platform that combines AI, metagenomics, and high-throughput T-cell screening to discover molecules that drastically amplify immune responses, unlocking targeted, effective, and safe treatment for cancers and autoimmune diseases where current therapies fall short.
Funding snapshot
- Total raised
- $4.7MSum of rounds, as of 2026-09-17Source (opens in a new tab)
- Latest round
- Pre seed, $3.7M2026-02-17
Funding rounds
- Pre seed
- $3.7M2026-02-17, Company stated
- Round, 2025
- $3.8M2025-11-25, SEC form D sold, 15 investors
- Grant
- $1M2024-09-10, Company stated
Products
- Other
- SIFT™ Platform
Loading relationship preview